$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2019 Form 10-K Financial Statement

#000156459020007591 Filed on February 28, 2020

Income Statement

Concept	2019	2018 Q4	2018
Revenue	$272.3M	$71.08M	$251.0M
YoY Change	8.47%	228.95%	806.6%
Cost Of Revenue	$36.82M	$10.36M	$34.62M
YoY Change	6.34%	155.8%	521.34%
Gross Profit	$235.4M	$60.72M	$216.4M
YoY Change	8.82%	245.79%	878.47%
Gross Profit Margin	86.48%	85.43%	86.21%
Selling, General & Admin	$141.6M	$40.93M	$146.2M
YoY Change	-3.11%	32.59%	37.02%
% of Gross Profit	60.16%	67.41%	67.56%
Research & Development	$132.9M	$38.33M	$164.9M
YoY Change	-19.41%	-23.72%	-20.67%
% of Gross Profit	56.43%	63.13%	76.19%
Depreciation & Amortization	$900.0K	$2.100M	$1.100M
YoY Change	-18.18%	54.41%	0.0%
% of Gross Profit	0.38%	3.46%	0.51%
Operating Expenses	$311.4M	$79.26M	$345.7M
YoY Change	-9.92%	-2.29%	7.99%
Operating Profit	-$39.05M	-$18.54M	-$94.67M
YoY Change	-58.76%	-70.83%	-67.62%
Interest Expense	$15.02M	-$3.120M	$10.99M
YoY Change	36.72%	524.0%	1425.69%
% of Operating Profit
Other Income/Expense, Net	-$36.50M	-$20.00K	-$18.90M
YoY Change	93.08%	100.0%	-4445.52%
Pretax Income	-$75.54M	-$30.68M	-$113.6M
YoY Change	-33.48%	-52.12%	-61.11%
Income Tax	$53.00K	$20.00K	$17.00K
% Of Pretax Income
Net Earnings	-$75.60M	-$30.69M	-$113.6M
YoY Change	-33.44%	-52.1%	-61.1%
Net Earnings / Revenue	-27.77%	-43.18%	-45.25%
Basic Earnings Per Share	-$75.60K
Diluted Earnings Per Share	-$1.948M	-$803.7K	-$2.997M
COMMON SHARES
Basic Shares Outstanding		38.13M
Diluted Shares Outstanding

Balance Sheet

Concept	2019	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$111.6M	$165.4M	$165.4M
YoY Change	-32.53%	102.45%	102.45%
Cash & Equivalents	$60.00M	$108.4M	$108.4M
Short-Term Investments	$51.60M	$57.00M	$57.00M
Other Short-Term Assets	$22.60M	$1.787M	$13.00M
YoY Change	73.85%	-86.25%	0.0%
Inventory	$3.200M	$2.625M	$2.600M
Prepaid Expenses		$12.40M
Receivables	$26.40M	$20.77M	$20.80M
Other Receivables	$2.500M	$1.100M	$1.100M
Total Short-Term Assets	$166.3M	$203.0M	$203.0M
YoY Change	-18.08%	90.8%	90.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.80M	$3.963M	$4.000M
YoY Change	445.0%	-11.34%	-11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.300M	$7.700M	$7.700M
YoY Change	-18.18%	22.22%	22.22%
Total Long-Term Assets	$68.60M	$56.12M	$56.10M
YoY Change	22.28%	-5.09%	-5.08%
TOTAL ASSETS
Total Short-Term Assets	$166.3M	$203.0M	$203.0M
Total Long-Term Assets	$68.60M	$56.12M	$56.10M
Total Assets	$234.9M	$259.1M	$259.1M
YoY Change	-9.34%	56.55%	56.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.20M	$20.68M	$20.70M
YoY Change	-7.25%	-25.31%	-25.27%
Accrued Expenses	$71.70M	$46.43M	$46.40M
YoY Change	54.53%	51.5%	51.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$90.80M	$67.12M	$67.10M
YoY Change	35.32%	15.04%	15.09%
LONG-TERM LIABILITIES
Long-Term Debt	$95.00M	$151.9M	$151.9M
YoY Change	-37.46%	213.2%	213.2%
Other Long-Term Liabilities	$31.60M	$5.800M	$5.800M
YoY Change	444.83%	7.41%	7.41%
Total Long-Term Liabilities	$126.6M	$157.7M	$157.7M
YoY Change	-19.72%	192.58%	192.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$90.80M	$67.12M	$67.10M
Total Long-Term Liabilities	$126.6M	$157.7M	$157.7M
Total Liabilities	$217.4M	$224.8M	$224.8M
YoY Change	-3.29%	100.33%	100.36%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.202B
YoY Change		10.43%
Common Stock		$1.236B
YoY Change		8.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.50M	$34.31M	$34.30M
YoY Change
Total Liabilities & Shareholders Equity	$234.9M	$259.1M	$259.1M
YoY Change	-9.34%	56.55%	56.56%

Cashflow Statement

Concept	2019	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$75.60M	-$30.69M	-$113.6M
YoY Change	-33.44%	-52.1%	-61.1%
Depreciation, Depletion And Amortization	$900.0K	$2.100M	$1.100M
YoY Change	-18.18%	54.41%	0.0%
Cash From Operating Activities	$22.38M	$7.040M	-$24.11M
YoY Change	-192.83%	-119.77%	-86.02%
INVESTING ACTIVITIES
Capital Expenditures	$306.0K	-$60.00K	$439.0K
YoY Change	-30.3%	-99.88%	1.86%
Acquisitions
YoY Change
Other Investing Activities	$5.470M	$2.650M	-$57.01M
YoY Change	-109.59%	-90.05%	-262.89%
Cash From Investing Activities	$5.163M	$2.590M	-$57.62M
YoY Change	-108.96%	-111.01%	273.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$67.07M	30.49M	108.5M
YoY Change	-161.84%	-50.11%	44.39%
NET CHANGE
Cash From Operating Activities	$22.38M	7.040M	-24.11M
Cash From Investing Activities	$5.163M	2.590M	-57.62M
Cash From Financing Activities	-$67.07M	30.49M	108.5M
Net Change In Cash	-$39.53M	40.12M	26.72M
YoY Change	-247.92%	1926.26%	-123.69%
FREE CASH FLOW
Cash From Operating Activities	$22.38M	$7.040M	-$24.11M
Capital Expenditures	$306.0K	-$60.00K	$439.0K
Free Cash Flow	$22.07M	$7.100M	-$24.54M
YoY Change	-189.92%	-51.14%	-85.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-35703
CY2019	dei	Entity Registrant Name EntityRegistrantName	PUMA BIOTECHNOLOGY, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0683487
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2150
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2019	dei	City Area Code CityAreaCode	424
CY2019	dei	Local Phone Number LocalPhoneNumber	248-6500
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001401667
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Lessee Operating Lease Existence Of Option To Terminate LesseeOperatingLeaseExistenceOfOptionToTerminate	true
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2017	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y4M24D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2018	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y3M18D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2019	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2019	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	10880 Wilshire Boulevard
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2019Q2	dei	Entity Public Float EntityPublicFloat	427600000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2811000
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1796000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	1256000
CY2019	us-gaap	Interest Expense InterestExpense	15019000
CY2018	us-gaap	Interest Expense InterestExpense	10985000
CY2019	pbyi	Legal Verdict Expenses LegalVerdictExpenses	16350000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	209824000
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39301587
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108419000
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	57002000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20773000
CY2018Q4	us-gaap	Inventory Net InventoryNet	2625000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12397000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27685000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60037000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51607000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28896000
CY2019Q4	us-gaap	Inventory Net InventoryNet	3170000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13259000
CY2019Q4	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	154000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1787000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	203003000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2624000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	90837000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67115000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	5815000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22643000
CY2019Q4	pbyi	Post Marketing Commitment Liability Noncurrent PostMarketingCommitmentLiabilityNoncurrent	9000000
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	94962000
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	151886000
CY2019Q4	us-gaap	Liabilities Liabilities	217442000
CY2018Q4	us-gaap	Liabilities Liabilities	224816000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39203304
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39203304
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38325037
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38325037
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1295033000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1236355000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	62000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1277636000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1202041000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17463000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	34306000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	234905000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259122000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250991000
CY2017	pbyi	Cost Of Sales CostOfSales	5572000
CY2019	us-gaap	Operating Expenses OperatingExpenses	311358000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36497000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-113575000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75595000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-113575000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-291955000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-39098000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-94672000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2847000
CY2017	us-gaap	Interest Expense InterestExpense	720000
CY2018	pbyi	Legal Verdict Expenses LegalVerdictExpenses	9000000
CY2019	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8103000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	128000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-714000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-101000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18903000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	435000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.95
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.99
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.85
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38768653
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37942411
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37169678
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-75595000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-113575000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-291955000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	72000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75521000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113587000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-291942000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108735000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	26685000
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-291955000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	53302000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	86939000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7652000
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-12000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-113575000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	34306000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57327000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1351000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	72000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-75595000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17463000
CY2019	us-gaap	Profit Loss ProfitLoss	-75595000
CY2018	us-gaap	Profit Loss ProfitLoss	-113575000
CY2017	us-gaap	Profit Loss ProfitLoss	-291955000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8077000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7384000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	57327000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	86939000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	108735000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-54000
CY2019	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-1183000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8047000
CY2018	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-289000
CY2019	pbyi	Fixed Lease Expense FixedLeaseExpense	4700000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	400000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8123000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11103000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9670000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	545000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	596000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2029000
CY2019	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-568000
CY2018	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	840000
CY2017	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1142000
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1464000
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1787000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1526000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7008000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7657000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	22599000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15783000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13222000
CY2019	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	154000
CY2018	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	-409000
CY2017	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	99000
CY2019	pbyi	Increase Decrease In Post Marketing Commitment Liability IncreaseDecreaseInPostMarketingCommitmentLiability	9000000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22376000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24105000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-172470000
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	50000000
CY2019	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	306000
CY2018	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	439000
CY2017	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	431000
CY2018	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	170000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	127198000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	107502000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	79729000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	28135000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	104532000
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	50488000
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	114724000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5163000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57623000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15436000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1351000
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7652000
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	26685000
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	25000000
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	105000000
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	80000000
CY2019	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	7793000
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5625000
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4201000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1575000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-67067000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108451000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75110000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39528000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26723000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-112796000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112738000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86015000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	198811000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73210000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112738000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86015000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	25000
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000
CY2017	pbyi	Receivables Related To Stock Option Exercises ReceivablesRelatedToStockOptionExercises	449000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	11739000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	8055000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	344000
CY2019	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-75600000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22400000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60000000.0
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51600000
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p>
CY2019Q4	pbyi	Incremental Costs Expenses IncrementalCostsExpenses	0
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	13200000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	4300000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92840000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	62000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92902000
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	143330000
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	143318000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at December 31, 2019, were approximately $77.3 million. The Company does not believe it is exposed to any significant credit risk due to the quality </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0 as an allowance for doubtful accounts in the years ended December 31, 2019, 2018, and 2017.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</span></p>
CY2019Q4	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	77300000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2017	pbyi	Research And Development Expense Related To Inventory ResearchAndDevelopmentExpenseRelatedToInventory	4500000
CY2019	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2019	us-gaap	Lessee Operating Lease Option To Terminate LesseeOperatingLeaseOptionToTerminate	Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2019Q1	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109
CY2019Q4	pbyi	Lessee Sublease Discount Rate LesseeSubleaseDiscountRate	0.109
CY2019Q4	pbyi	Reduction In Carrying Value Of Right Of Use Asset ReductionInCarryingValueOfRightOfUseAsset	1200000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Eight FiniteLivedIntangibleAssetsAmortizationExpenseYearEight	3900000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Nine FiniteLivedIntangibleAssetsAmortizationExpenseYearNine	3900000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3900000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3900000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3900000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3900000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3900000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	3900000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Seven FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven	3900000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Ten FiniteLivedIntangibleAssetsAmortizationExpenseYearTen	3900000
CY2019Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Eleven FiniteLivedIntangibleAssetsAmortizationExpenseYearEleven	1000000.0
CY2019Q4	pbyi	Accounts Receivable Net Excluding License Revenue Receivable AccountsReceivableNetExcludingLicenseRevenueReceivable	26396000
CY2018Q4	pbyi	Accounts Receivable Net Excluding License Revenue Receivable AccountsReceivableNetExcludingLicenseRevenueReceivable	20773000
CY2019Q4	pbyi	License Revenue Receivable LicenseRevenueReceivable	2500000
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	28896000
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	20773000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13259000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12397000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1999000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3429000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	15258000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	15826000
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1788436
CY2018Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	1175000
CY2019Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	323000
CY2018Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	612000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	323000
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1787000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9163000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9139000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5859000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5176000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3304000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3963000
CY2019	us-gaap	Depreciation Depreciation	900000
CY2018	us-gaap	Depreciation Depreciation	1100000
CY2017	us-gaap	Depreciation Depreciation	1100000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4700000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3900000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5207000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5365000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5483000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5631000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5805000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7491000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	34982000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9715000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	25267000
CY2019	us-gaap	Sublease Income SubleaseIncome	200000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	416000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	467000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	481000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	495000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	510000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	659000
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3028000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	5438000
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109
CY2019Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	50000000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9539000
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	40461000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3947000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3947000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3947000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3947000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3947000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	20726000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40461000
CY2019Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	31350000
CY2019Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2546000
CY2018Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2380000
CY2018Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	9000000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8866000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9162000
CY2019Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	8502000
CY2018Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	10187000
CY2019Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	7978000
CY2018Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	3818000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1618000
CY2018Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1705000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4138000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4435000
CY2019Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1775000
CY2018Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	2175000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	266000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1379000
CY2019Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	869000
CY2018Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	788000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1122000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1402000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69030000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46431000
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	100000000
CY2019	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-06-01
CY2019Q4	pbyi	Accretion Of Final Interest Payment AccretionOfFinalInterestPayment	1929000
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	6967000
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	94962000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	790642
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	529443
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	211761
CY2019Q4	pbyi	Common And Preferred Stock Shares Authorized Before Amendment CommonAndPreferredStockSharesAuthorizedBeforeAmendment	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2021-10-04
CY2019	pbyi	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	57327000
CY2018	pbyi	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	86939000
CY2017	pbyi	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	108735000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6578522
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	87.52
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18442000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	519791
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	38.87
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	285377
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	50.11
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	557080
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	48.71
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	27185000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	121343
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	125.40
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6134513
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	87.91
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220060000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	315566
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	59.13
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	183837
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	51.96
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	200743
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	35.88
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5063000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	356955
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	116.96
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5708544
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	87.49
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7762000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	340241
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.40
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	128406
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	38.71
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87625
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.42
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	995000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	790429
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	104.76
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5042325
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	82.42
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1951000
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	439194
CY2019Q4	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	25.14
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4603131
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	87.88
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1746000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.08
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.62
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.30
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	33.37
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	315566
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.62
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1140873
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	36.81
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	183837
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	31.43
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	779292
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	33.75
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	340241
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.08
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	551933
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	33.56
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	128406
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	26.27
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	439194
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	19.38
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1900000
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	53000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	53000
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	17000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	21000000.0
CY2019	pbyi	Income Tax Benefit Due To Research And Development Tax Credits IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits	15200000
CY2019	pbyi	Income Tax Benefit Due To Release Of Uncertain Tax Positions IncomeTaxBenefitDueToReleaseOfUncertainTaxPositions	8400000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15830000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23771000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-99234000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2453000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2791000
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-15890000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	21834000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	10932000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1404000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	14946000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5630000
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6217000
CY2017	pbyi	Income Tax Reconciliation Deferred Tax Asset Adjustment IncomeTaxReconciliationDeferredTaxAssetAdjustment	6805000
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	141147000
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2792000
CY2018	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	15750000
CY2017	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-20000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14240000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5527000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-25187000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	260555000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	257021000
CY2019Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	50343000
CY2018Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	35107000
CY2019Q4	pbyi	Deferred Tax Assets Organization Costs DeferredTaxAssetsOrganizationCosts	10472000
CY2018Q4	pbyi	Deferred Tax Assets Organization Costs DeferredTaxAssetsOrganizationCosts	3593000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	60967000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	72804000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	1404000
CY2019Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	6145000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	388495000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	369929000
CY2019Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	4505000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	76000
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	255000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4581000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	255000
CY2019Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	383914000
CY2018Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	369674000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	383914000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	369674000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14200000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5500000
CY2019	pbyi	Operating Loss Carryforwards Expiration Dates Federal OperatingLossCarryforwardsExpirationDatesFederal	2033
CY2019	pbyi	Operating Loss Carryforwards Expiration Dates State OperatingLossCarryforwardsExpirationDatesState	2031
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8777000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7151000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5315000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8422000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1613000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1626000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1836000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1968000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8777000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7151000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-11199000
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10087000
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37424000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16885000
CY2019Q4	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	97798000
CY2019Q4	pbyi	Potential Milestone Payments PotentialMilestonePayments	20200000
CY2019Q4	pbyi	Success Based Legal Fee SuccessBasedLegalFee	3000000.0
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	99067000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53919000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56352000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62922000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10087000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37424000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-16885000
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11199000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38481824
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38647775
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38893757
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39043706
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66516000
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50767000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62629000
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71079000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-24345000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-44335000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-14201000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-30694000
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24345000
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44335000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14201000
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30694000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37699024
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37819767
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38043174
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38201056
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6077000
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21608000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-72865000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-77832000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-77180000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-64078000
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-72865000
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77832000
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77180000
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-64078000
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.10
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.07
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.71
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36931167
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36992017
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37214002
CY2017Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37534410

Files In Submission

Name	View Source	Status
0001564590-20-007591-index-headers.html	Edgar Link	pending
0001564590-20-007591-index.html	Edgar Link	pending
0001564590-20-007591.txt	Edgar Link	pending
0001564590-20-007591-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gqjxenz4wv5r000001.jpg	Edgar Link	pending
gqjxenz4wv5r000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-10k_20191231.htm	Edgar Link	pending
pbyi-10k_20191231_htm.xml	Edgar Link	completed
pbyi-20191231.xsd	Edgar Link	pending
pbyi-20191231_cal.xml	Edgar Link	unprocessable
pbyi-20191231_def.xml	Edgar Link	unprocessable
pbyi-20191231_lab.xml	Edgar Link	unprocessable
pbyi-20191231_pre.xml	Edgar Link	unprocessable
pbyi-ex1017b_376.htm	Edgar Link	pending
pbyi-ex1018b_375.htm	Edgar Link	pending
pbyi-ex1018c_374.htm	Edgar Link	pending
pbyi-ex211_7.htm	Edgar Link	pending
pbyi-ex231_11.htm	Edgar Link	pending
pbyi-ex311_9.htm	Edgar Link	pending
pbyi-ex312_10.htm	Edgar Link	pending
pbyi-ex321_12.htm	Edgar Link	pending
pbyi-ex322_14.htm	Edgar Link	pending
pbyi-ex43_373.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2019 Form 10-K Financial Statement

#000156459020007591 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2019 Form 10-K Financial Statement

#000156459020007591 Filed on February 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi